South Korean biotech GI Innovation files patent for next-generation pulmonary arterial hypertension candidate, The Bio, April 29, 2026

GI Innovation, a South Korean bio-venture company, announced on April 29, 2026, that it has filed a domestic patent application for GI-214 (development code), a pulmonary arterial hypertension (PAH) treatment candidate. GI-214 is positioned as a next-generation candidate targeting the same disease-associated signaling pathway (the activin pathway) as sotatercept, the therapy developed by MSD (Merck […]

South Korean biotech GI Innovation files patent for next-generation pulmonary arterial hypertension candidate, The Bio, April 29, 2026 Read Post »

Progress on xenotransplantation and bioengineered organs, the potential next growth frontier for United Therapeutics

United Therapeutics is making a major strategic bet on xenotransplantation and bioengineered organs as its primary long-term growth driver. The is using genetically modified pig organs to reduce rejection risk — with its UHeart and UKidney programmes having already achieved transplants in living humans. In parallel, it is developing 3D-bioprinted lungs, livers and kidneys using

Progress on xenotransplantation and bioengineered organs, the potential next growth frontier for United Therapeutics Read Post »

Economic burden of pulmonary arterial hypertension in Switzerland, Plos One, April 28, 2026

A cross-sectional Swiss study involving 124 pulmonary arterial hypertension patients across six centres estimated the annual cost at nearly €139,000 per patient, with direct healthcare costs accounting for 78.5% of this figure — driven predominantly by pharmacological treatment, which alone represented 65% of total costs. Indirect costs, including productivity losses and informal care, made up

Economic burden of pulmonary arterial hypertension in Switzerland, Plos One, April 28, 2026 Read Post »

Monthly roundup of content shared on the Pulmonary Hypertension Knowledge Sharing Platform – April 2026

Welcome to our April roundup of the most relevant and interesting content shared on this platform. April 2026 has been a particularly rich month, with significant news on the diagnostics, clinical trials and treatment front alongside important research on quality of life, patient preferences information, economic burden. There is also a selection of patient resources

Monthly roundup of content shared on the Pulmonary Hypertension Knowledge Sharing Platform – April 2026 Read Post »

Exploring the potential of “synthetic” control arms in clinical trials to reduce trial size, speed up recruitment, cut costs, improve early stage decision making, The Scientist, April 25, 2026

Qureight, a data science company, is using synthetic control arms — trial groups generated from existing real-world and historical datasets rather than traditional placebo groups. Their approach involves repeatedly drawing random patient samples from external datasets and matching them to trial participants on key baseline characteristics, generating hundreds of potential control arms. The method has

Exploring the potential of “synthetic” control arms in clinical trials to reduce trial size, speed up recruitment, cut costs, improve early stage decision making, The Scientist, April 25, 2026 Read Post »

Pulnovo Medical and Medtronic Join Forces to Advance Pulmonary Artery Denervation for Pulmonary Hypertension, Pulse 2.0, April 25, 2026

Pulnovo Medical, a Shanghai-based company developing therapies for pulmonary hypertension and heart failure, has raised $100 million in a strategic financing round led by Medtronic, which has also entered into a separate commercial agreement with the company exploring future commercialisation opportunities. Pulnovo’s flagship product is the Pulmonary Artery Denervation (PADN) System, a minimally invasive device

Pulnovo Medical and Medtronic Join Forces to Advance Pulmonary Artery Denervation for Pulmonary Hypertension, Pulse 2.0, April 25, 2026 Read Post »

Join the “Global Pulmonary Hypertension Patient Hackathon” organised by the Global Allergy & Airways Patient Platform (GAAPP) and Latin Health Leaders (LDL) on June 10-11, 2026!

Within the framework of the PHA 2026 International Conference (June 11-14 in Dallas, Texas), the Global Allergy & Airways Patient Platform (GAAPP) and Latin Health Leaders (LDL) will convene the “Global Pulmonary Hypertension Patient Hackathon“, taking place on June 10 (full day) and June 11 (half day), with the strategic support of the Pulmonary Vascular Research Institute (PVRI) and the Pulmonary Hypertension

Join the “Global Pulmonary Hypertension Patient Hackathon” organised by the Global Allergy & Airways Patient Platform (GAAPP) and Latin Health Leaders (LDL) on June 10-11, 2026! Read Post »

The Canadian Pulmonary Hypertension Association, PHA Canada, launches its “PH Peer Mentor Program”, April 2026

The Canadian Pulmonary Hypertension Association (PHA Canada) has launched a “Pulmonary Hypertension Peer Mentor Program”, designed to connect patients and caregivers with trained volunteers. The peer mentors offer a supportive ear, share practical insights, and provide helpful resources based on their own lived experience with pulmonary hypertension. Read more on the PHA Canada website at

The Canadian Pulmonary Hypertension Association, PHA Canada, launches its “PH Peer Mentor Program”, April 2026 Read Post »

Quality of life in patients with pulmonary arterial hypertension: A systematic review and meta-analysis, Health Quality of Life Outcomes, April 13, 2026

The importance of patient-reported outcome measures (PROMs) in assessing health-related QoL has been increasingly recognized, but their implementation remains inconsistent in clinical practice. A systematic review published on April 13, 2026 on Health Quality of Life Outcomes has synthesized the available evidence on the impact of pulmonary arterial hypertension on patients’ QoL measured by PROMs.

Quality of life in patients with pulmonary arterial hypertension: A systematic review and meta-analysis, Health Quality of Life Outcomes, April 13, 2026 Read Post »

GSK completes acquisition of 35Pharma, whose investigational drug HS235 for the treatment of pulmonary arterial hypertension targets the activin receptor signalling pathway

GSK has completed the acquisition of 35Pharma, a Canadian clinical-stage biopharmaceutical company. The key asset is HS235, a molecule targeting the activin receptor signalling pathway — the same pathway as sotatercept — designed for the treatment of pulmonary arterial hypertension. HS235 is engineered for greater selectivity than existing agents, with the aim of reducing side

GSK completes acquisition of 35Pharma, whose investigational drug HS235 for the treatment of pulmonary arterial hypertension targets the activin receptor signalling pathway Read Post »

Understanding how the right heart catheterisation works, the UK Pulmonary Hypertension Association (PHA UK)’s video of the month, April 2026

The right heart catheter – also known as cardiac catheterisation, and abbreviated as RHC –is considered the “gold standard’ test to diagnose pulmonary arterial hypertension, and at follow up to monitor progress of the condition and efficacy of treatments. In this video Dr Charlie Elliott, from the Sheffield Pulmonary Vascular Disease Unit, who has performed

Understanding how the right heart catheterisation works, the UK Pulmonary Hypertension Association (PHA UK)’s video of the month, April 2026 Read Post »

UK Pulmonary Hypertension Association opens Poetry Competition to the pulmonary hypertension community

The UK Pulmonary Hypertension Association (PHA UK) is inviting everyone in the pulmonary community to enter their Poetry Competition — patients, caregivers, family members, friends, and healthcare professionals alike. It’s free to enter. These are some of the topics suggested: 👉 Visit the PHA UK website to enter.

UK Pulmonary Hypertension Association opens Poetry Competition to the pulmonary hypertension community Read Post »

The latest edition of “Connections”, the Canadian Pulmonary Hypertension Association (PHA Canada)’s twice-yearly magazine, is dedicated to raising awareness of organ donation and transplant

This month, The Canadian Pulmonary Hypertension Association PHA Canada is raising awareness about the life-changing impact of organ and tissue donation. The newest issue of their magazine Connections is dedicated to Transplant & Pulmonary Hypertension, and it explores this important topic through stories, insights, and resources from the community. 👉 Subscribe to Connections and receive

The latest edition of “Connections”, the Canadian Pulmonary Hypertension Association (PHA Canada)’s twice-yearly magazine, is dedicated to raising awareness of organ donation and transplant Read Post »

CardioMEMS-guided therapy shows promising results in pulmonary arterial hypertension: ARTISAN interim analysis presented at the American College of Cardiology Congress 2026, March 28–30

One of the most talked-about moments at this year’s American College of Cardiology Scientific Session was the presentation of the ARTISAN interim analysis by Dr. Raymond Benza — a study that was voted one of the Top 4 abstracts in Pulmonary Hypertension. ARTISAN (Afterload Reduction To Improve Right Ventricular Structure And FuNction), is a prospective, multicenter, open-label clinical

CardioMEMS-guided therapy shows promising results in pulmonary arterial hypertension: ARTISAN interim analysis presented at the American College of Cardiology Congress 2026, March 28–30 Read Post »

Walk4PH Nigeria: A Community Steps Up for Pulmonary Hypertension Awareness, May 16, 2026

Here is a short report: Walk4PH is a growing awareness initiative founded by Ayotunde Omitogun, a pulmonary hypertension patient and founder of the Cardiac Community, a Nigerian non-profit organisation dedicated to improving the lives of people living with heart and lung conditions. This year, Walk4PH has evolved into something larger than a single event. Built

Walk4PH Nigeria: A Community Steps Up for Pulmonary Hypertension Awareness, May 16, 2026 Read Post »

The Canadian Pulmonary Hypertension Association (PHA Canada) launches an Advisory Council bringing together patients and caregivers to help shape its future programs and priorities

The Canadian Pulmonary Hypertension Association (PHA Canada) has recently announced the setting up of a “Patient Partner Advisory Council (PPAC)”—a new committee which brings together patients and caregivers to help shape the future of the pulmonary hypertension community. The founding members are Angèle Belliveau, Don Downey, Maureen Harper, Brooke Paulin, and Jane Sernoskie. Their lived experience

The Canadian Pulmonary Hypertension Association (PHA Canada) launches an Advisory Council bringing together patients and caregivers to help shape its future programs and priorities Read Post »

Self-Image and pulmonary hypertension: a study supported by the UK Pulmonary Hypertension Association explores how living with the condition can shape the way patients see themselves

With the support of the UK Pulmonary Hypertension Association (PHA UK), trainee psychologist Jacob Pendrey, at Cardiff University in Wales, conducted a study exploring how pulmonary hypertension affects self-image — and the findings are both striking and important. Pulmonary hypertension is known to alter daily life not only through physical limitations, but through profound social

Self-Image and pulmonary hypertension: a study supported by the UK Pulmonary Hypertension Association explores how living with the condition can shape the way patients see themselves Read Post »

The US Pulmonary Hypertension Association, the PHA, celebrates its 35th anniversary this year, read more on the latest edition of its magazine Pathlight

As US Pulmonary Hypertension Association, celebrates its 35th anniversary this year, founders Judy and Ed Simpson reflect on the organization’s history in the latest issue of Pathlight magazine. Check out the timeline at this link The Pulmonary Hypertension Association (PHA) was founded in 1991 by three patients and a nurse in Florida, and has grown

The US Pulmonary Hypertension Association, the PHA, celebrates its 35th anniversary this year, read more on the latest edition of its magazine Pathlight Read Post »

Inhibikase Therapeutics begins pivotal phase 3 trial in pulmonary arterial hypertension, April 7, 2026

Inhibikase Therapeutics has enrolled the first patient in its global pivotal Phase 3 IMPROVE-PAH trial of IKT-001 for pulmonary arterial hypertension. The trial uses a two-part adaptive design: the first part evaluates change in pulmonary vascular resistance in approximately 140 patients over 12 weeks, followed by a second part focusing on six-minute walk distance in

Inhibikase Therapeutics begins pivotal phase 3 trial in pulmonary arterial hypertension, April 7, 2026 Read Post »

Review of Pulmonary Arterial Hypertension (PAH) research in 2025: key trends and what they mean for patients, Pulmonary Therapy, April 8, 2026

A descriptive analysis of 54 pulmonary arterial hypertension-related clinical studies registered on international platforms in 2025 was recently published in Pulmonary Therapeutics. The review reveals an evolving and increasingly sophisticated research landscape. Nearly two thirds of the studies were interventional and one third observational, with most involving pharmacological interventions. Most trials involved pharmacological interventions and

Review of Pulmonary Arterial Hypertension (PAH) research in 2025: key trends and what they mean for patients, Pulmonary Therapy, April 8, 2026 Read Post »

TRANSLATE »
Scroll to Top